BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12698179)

  • 1. Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer.
    Kosmas C; Tsavaris N; Malamos N; Stavroyianni N; Gregoriou A; Rokana S; Polyzos A
    Br J Cancer; 2003 Apr; 88(8):1168-74. PubMed ID: 12698179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
    Kosmas C; Tsavaris N; Mylonakis N; Tsakonas G; Gassiamis A; Skopelitis H; Polyzos A; Malamos N; Karabelis A
    J Chemother; 2007 Jun; 19(3):322-31. PubMed ID: 17594929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose escalation of docetaxel and ifosfamide in patients with advanced breast cancer failing prior anthracyclines: mature results of a phase I-II study.
    Cosmas C; Tsavaris N; Malamos N; Tsakonas G; Gassiamis A; Skopelitis H; Soukouli G; Polyzos A; Mylonakis N; Karabelis A
    J BUON; 2005; 10(3):337-46. PubMed ID: 17357187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.
    Kosmas C; Tsavaris N; Malamos N; Tsakonas G; Gassiamis A; Polyzos A; Mylonakis N; Karabelis A
    Invest New Drugs; 2007 Oct; 25(5):463-70. PubMed ID: 17370037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
    Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
    Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
    Awada A; Albanell J; Canney PA; Dirix LY; Gil T; Cardoso F; Gascon P; Piccart MJ; Baselga J
    Br J Cancer; 2008 May; 98(9):1500-7. PubMed ID: 18454159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
    Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
    Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
    Delozier T; Guastalla JP; Yovine A; Levy C; Chollet P; Mousseau M; Delva R; Coeffic D; Vannetzel JM; Zazzi ES; Brienza S; Cvitkovic E
    Anticancer Drugs; 2006 Oct; 17(9):1067-73. PubMed ID: 17001180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
    Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
    Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
    Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M
    Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer.
    Kosmas C; Agelaki S; Giannakakis T; Mavroudis D; Kouroussis Ch; Kalbakis K; Papadouris S; Souglakos J; Malamos N; Georgoulias V
    Oncology; 2002; 62(2):103-9. PubMed ID: 11914594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
    Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
    Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
    Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
    Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
    Kosmas C; Tsavaris NB; Polyzos A; Malamos NA; Katsikas M; Antonopoulos MJ
    Br J Cancer; 2000 Jan; 82(2):300-7. PubMed ID: 10646881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
    Kosmas C; Tsavaris N; Koutras A; Makatsoris T; Mylonakis N; Tzelepis G; Dimitrakopoulos A; Spyropoulos K; Polyzos A; Karabelis A; Kalofonos HP
    Oncology; 2005; 69(4):333-41. PubMed ID: 16282711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
    Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
    Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
    Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer.
    Lortholary A; Delozier T; Monnier A; Bourgeois H; Bougnoux P; Tubiana-Mathieu N; Riffaud JCh; Besson D; Lotz V; Gamelin E
    Br J Cancer; 2003 Jun; 88(11):1669-74. PubMed ID: 12771978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.